Wednesday, December 6, 2023 |

Md. biotech strikes deal with Gilead potentially worth more than $1.7B

October 18, 2022

The Maryland biotech also received $30 million in milestone payments after licensing retifanlimab to Incyte Corp., and could receive more if the drug, now in clinical trials, is later approved. MacroGenics separately expects to start a phase 2/3 study by year’s end of a candidate in patients with a form of advanced prostate cancer, and has another candidate in early-stage studies for colorectal cancer, nonsmall cell lung cancer, metastatic prostate cancer and melanoma.

Article Source: Baltimore Business Journal

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.